Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis

被引:11
作者
Peterson, ML
Rotschafer, JC
Piddock, LJV [1 ]
机构
[1] Univ Birmingham, Sch Med, Div Immun & Infect, Antimicrobial Agents Res Grp, Birmingham B15 2TT, W Midlands, England
[2] Univ Minnesota, Minneapolis, MN USA
关键词
anaerobe; quinolone; antibiotic resistance;
D O I
10.1093/jac/dkg368
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To identify whether mutations in gyrA and gyrB confer fluoroquinolone resistance in Bacteroides fragilis. Methods: Eight fluoroquinolone-resistant (FQ(R)) strains were complemented with plasmid-mediated B. fragilis wild-type gyrA (pMP1) and gyrB (pMP2), and MICs determined. Sequence analysis of the gyrA and gyrB quinolone resistance determining region (QRDR) was performed for all strains. Results: MICs of fluoroquinolones were two- to 32-fold higher than wild-type for all mutants. Five mutants had a substitution in GyrA (Ser-82-->Phe), one mutant had a substitution in GyrA (Asp-81-->Gly), one mutant had a substitution in GyrB (Glu-478-->Lys), and one resistant strain did not contain mutations in the QRDR of gyrA or gyrB. Following complementation with pMP1 or pMP2, the MICs of fluoroquinolones were reduced two- to 32-fold for the mutants. Conclusion: These studies verify that substitutions in GyrA and GyrB confer resistance in B. fragilis. Other mechanisms are also responsible for resistance since not all resistant strains fully complemented to the wild-type phenotype.
引用
收藏
页码:481 / 484
页数:4
相关论文
共 10 条
[1]   Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin [J].
Bachoual, R ;
Dubreuil, L ;
Soussy, CJ ;
Tankovic, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1842-1845
[2]   LOCATION AND CHARACTERISTICS OF THE TRANSFER REGION OF A BACTEROIDES CONJUGATIVE TRANSPOSON AND REGULATION OF TRANSFER GENES [J].
LI, LY ;
SHOEMAKER, NB ;
SALYERS, AA .
JOURNAL OF BACTERIOLOGY, 1995, 177 (17) :4992-4999
[3]   GYRA AND GYRB MUTATIONS IN QUINOLONE-RESISTANT STRAINS OF ESCHERICHIA-COLI [J].
NAKAMURA, S ;
NAKAMURA, M ;
KOJIMA, T ;
YOSHIDA, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (02) :254-255
[4]   gyrA Mutations associated with quinolone resistance in Bacteroides fragilis group strains [J].
Oh, H ;
El Amin, N ;
Davies, T ;
Appelbaum, PC ;
Edlund, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :1977-1981
[5]   Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase [J].
Onodera, Y ;
Sato, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) :2423-2429
[6]   Pharmaco dynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model [J].
Peterson, ML ;
Hovde, LB ;
Wright, DH ;
Brown, GH ;
Hoang, AD ;
Rotschafer, JC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :203-210
[7]   Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure [J].
Peterson, ML ;
Hovde, LB ;
Wright, DH ;
Hoang, AD ;
Raddatz, JK ;
Boysen, PJ ;
Rotschafer, JC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2251-2255
[8]   BROAD-HOST-RANGE GYRASE-A GENE PROBE [J].
ROBILLARD, NJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (10) :1889-1894
[9]   National survey on the susceptibility of Bacteroides fragilis group:: Report and analysis of trends for 1997-2000 [J].
Snydman, DR ;
Jacobus, NV ;
McDermott, LA ;
Ruthazer, R ;
Goldstein, EJC ;
Finegold, SM ;
Harrell, LJ ;
Hecht, DW ;
Jenkins, SG ;
Pierson, C ;
Venezia, R ;
Rihs, J ;
Gorbach, SL .
CLINICAL INFECTIOUS DISEASES, 2002, 35 :S126-S134
[10]   In vitro activities of newer quinolones against Bacteroides group organisms [J].
Snydman, DR ;
Jacobus, NV ;
McDermott, LA ;
Ruthazer, R ;
Goldstein, E ;
Finegold, S ;
Harrell, L ;
Hecht, DW ;
Jenkins, S ;
Pierson, C ;
Venezia, R ;
Rihs, J ;
Gorbach, SL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (10) :3276-3279